Results from both studies were presented today at the 2015 Gastrointestinal Cancers Symposium in San Francisco, Calif. VT-122 is a novel, chrono-modulated combination of the non-selective beta-adrenergic receptor
The data, presented at the 2015 Gastrointestinal Cancers Symposium in San Francisco, Calif., point toward potential therapeutic options beyond standard-of-care immunomodulatory agents and pan-HER inhibitors for patients with
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that stimulates the secretion of insulin from the pancreas. Exenatide, a GLP-1 analog, is currently marketed in injectable form only, and
For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic
Speaking ahead of the eyeforpharma Barcelona 2015 conference, Alberto Grua, CCO at Grünenthalechoed similar industry commitments to putting patient’s needs to the forefront of their decision making, and
A provisional patent application is a legal document which establishes an early priority date for the benefit of claiming "first to file" status against other companies or individuals
CBD or Cannabidiol has been at the forefront of the news lately in its application to treat pediatric epilepsy, autism, cancer, pain, PTSD, brain injuries, anxiety, and various
With the construction of WCCT Global’s influenza challenge facility in Costa Mesa, California, the CRO has the capability to conduct virus challenge clinical trials in North America. WCCT
The Company also wishes to take this opportunity to better clarify the role of Hypochlorous acid in managing eyelid care. We believe that recent public statements concerning Hypochlorous
The invention relates to Crotoxin compositions for intravenous administration and methods of use of Crotoxin for the treatment of pain and/or for the treatment of neurologic and neuromuscular
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.